The global colon screening market was valued at USD 17.21 billion in 2024 and is projected to reach USD 22.21 billion by 2030, growing at a CAGR of 4.4% from 2025 to 2030. Market growth is primarily driven by the rising prevalence of colorectal cancer, increasing government initiatives aimed at promoting routine cancer screening, and continuous technological advancements that enhance detection accuracy and patient outcomes.
The growing incidence of colorectal diseases is a major demand driver. Colorectal cancer—one of the most serious gastrointestinal conditions—ranks as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths globally. According to the World Cancer Research Fund, approximately 1.93 million new colorectal cancer cases were reported worldwide in 2022, underscoring the urgent need for early detection and effective screening tools. The World Health Organization notes that regions such as Europe, Australia, and New Zealand report the highest incidence rates, driven by lifestyle habits, dietary patterns, and aging populations.
Key Market Trends & Insights
Download a free sample PDF of the Colon Screening Market Intelligence Study by Grand View Research.
Market Size & Forecast
Competitive Landscape
Key players in the colon screening industry are adopting strategies such as portfolio expansion, partnerships and collaborations, mergers and acquisitions, and geographic expansion to strengthen market presence. Innovations in AI-assisted diagnostics, minimally invasive screening solutions, and digital health platforms are further shaping competitive dynamics.
Prominent Companies
Recent Developments
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The colon screening market is poised for steady growth as healthcare providers, governments, and technology innovators intensify efforts to address rising colorectal cancer incidence. Advancements in AI, digital health platforms, and non-invasive testing methods will continue to enhance screening accuracy, expand patient access, and support earlier disease detection—ultimately improving global colorectal health outcomes.